James M. Frates - 05 Mar 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Reporting relationship: Chief Financial Officer
Issuer ticker: AMLX
Reported as of: 05 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Mar 2026, 16:00:07 UTC
Prior SEC filing: 04 Mar 2026
Next SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

James M. Frates filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 09 Mar 2026.

Key facts

This page summarizes James M. Frates's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Mar 2026, 16:00.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235598 Primary reporting owner

FRATES JAMES M

Relationship: Chief Financial Officer
Address: C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Award

Transaction value
Shares: +95,990
Change %: +58%
Price: $0.000000^*
Shares after: 261,628
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1

AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 05 Mar 2026
Ownership: By Trust
Footnotes: F2

AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 15,459
Date: 05 Mar 2026
Ownership: By Trust
Footnotes: F3

AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,072
Date: 05 Mar 2026
Ownership: By Trust
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMLX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +143,985
Change %
Price: $0.000000^*
Shares after: 143,985
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 143,985
Exercise price: $14.10
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Footnote F2

Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F3

Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F4

Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F5

25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.